Lisuride

From Wikipedia, the free encyclopedia

Lisuride
Systematic (IUPAC) name
1,1-diethyl-3-((6aR,9S)-7-methyl-

-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl)urea

Identifiers
CAS number 18016-80-3
ATC code G02CB02 N02CA07
PubChem 28864
DrugBank APRD00636
Chemical data
Formula C20H26N4O 
Mol. mass 338.447 g/mol
Pharmacokinetic data
Bioavailability 10-20% for lisuride hydrogenmaleate
Protein binding about 15%
Metabolism Hepatic
Half life 2 hours
Excretion renal and biliary in equal amounts
Therapeutic considerations
Pregnancy cat.

?

Legal status

Prescription only

Routes Oral, subcutaneous, transdermal

Lisuride (brand name in Germany Dopergin) is an anti-Parkinson's drug of the iso-ergoline class, chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride is described as free base (see table on the right) and as hydrogenmaleate salt.

Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks. The use of lisuride as initial anti-Parkinsonian treatment has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the Parkinsonian disability. Preliminary trials suggest that the dermal application of lisuride may be useful in the treatment of Parkinson's disease. Lisuride is not currently available in the US.

Contents

[edit] Mode of action

Lisuride is a dopamine agonist.

[edit] Commercial names

Name Country of Use
Arolac France
Cuvalit Germany
Dipergon Greece
Dopergin(e) Germany, Spain, France, China
Dopergine Belgium
Lysenyl Forte Czech Republic, Slovakia
Prolacam Australia
Revanil UK

[edit] History

Synthesis of lisuride was first described in 1960.

[edit] Indications

[edit] See also

Languages